Braidwell
VC Fund
Stamford, United States
Braidwell is a VC fund in Stamford focused on Biotechnology and Health Care. We serve the people and organizations that transform human health.
- Total investments:
- 36
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Braidwell invests in
BiotechnologyHealth CareBiopharmaTherapeuticsMedical
Stages Braidwell invests in
Post-IPO EquitySeries APost-IPO DebtSeries CFunding Round
Countries Braidwell invests in
United StatesFranceSwedenGermany
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Narendra Nayak
|
|||
|
Ilan Sender
|
|||
Investment Focus
Industry
- Biotechnology 29 (81%)
- Health Care 19 (53%)
- Biopharma 11 (31%)
- Therapeutics 11 (31%)
- Medical 7 (19%)
Stage
- Post-IPO Equity 20 (56%)
- Series A 4 (11%)
- Post-IPO Debt 3 (8%)
- Series C 2 (6%)
- Funding Round 2 (6%)
Country
- United States 29 (81%)
- France 1 (3%)
- Sweden 1 (3%)
- Germany 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Narendra Nayak
Partner
|
Partner | Total investments: 1 | Find email | |
|
Ilan Sender
Partner
|
Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Relmada Therapeutics
|
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor(NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.() | $160M / Post-IPO Equity / Mar 09, 2026 | |
Proxima
|
Proxima Bio develops programmable medicines that modulate protein interactions to address disease processes. It focuses on creating proximity-modulating therapeutics that direct protein interactions for potential use in conditions such as autoimmune disorders and cancer, expanding the range of targets that traditional drugs cannot easily reach.Proxima Bio combines structural biology, data generation, and machine learning to identify actionable protein-protein interfaces and support the discovery of new therapeutic modalities. The company works with pharmaceutical partners to apply its platform in research collaborations and advance drug discovery pipelines. Proxima Bio’s platform integrates multiple technologies to support the design and discovery of novel proximity-based treatment approaches. | $86.3M / Seed / Jan 13, 2026 | |
Alamar Biosciences
|
Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Hayward, California. | $50M / Convertible Note / Jan 11, 2026 | |
Impulse Dynamics
|
Impulse Dynamics is a medical device company dedicated to offering innovative solutions for treatment of Chronic Heart Failure (CHF). The Company’s developments are based on its proprietary technology for administering Cardiac Contractility Modulation therapy. This form of treatment has been shown in European clinical trials to produce an immediateand powerful modulating effect on cardiac cells, resulting in clinically meaningful increases incardiac performance.Impulse Dynamics is spearheaded by a team of professionals including, scientists, physicians, and engineers. The Company carries out research programs in major universities and hospitals throughout the world, and is currently engaged in clinical trials in Europe and in the United States. The Optimizer with Cardiac Contractility Modulation therapy, is CE marked. See Clinical Data for more information. | $158M / Dec 10, 2025 | |
Nurix Therapeutics
|
Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietaryDNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. | $250M / Post-IPO Equity / Oct 22, 2025 | |
Grail
|
Grail develops a pan-cancer screening test designed to detect cancers at an early stage. Its pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection.The company was founded in 2016 by AlexAravanis and Jeff Huber in Menlo Park, California. | $325M / Post-IPO Equity / Oct 20, 2025 | |
Lila Sciences
|
Lila Sciences is a platform that uses artificial intelligence to support research in life sciences, chemical sciences, and materials sciences. It develops AI-driven tools and autonomous labs to improve research efficiency and facilitate scientific discoveries. The platform is designed to enhance various aspects of the scientific method andcontribute to advancements in technology and innovation. | $235M / Series A / Sep 14, 2025 | |
Crescent Biopharma
|
Crescent Biopharma is a biotechnology firm focused on developing novel precision-engineered medicines targeting verified biology to improve care for patients with solid tumors. | $200M / Post-IPO Equity / Jun 16, 2025 | |
Jade Biosciences
|
Jade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications. | $300M / Post-IPO Equity / Apr 29, 2025 | |
Caris Life Sciences
|
Caris Life Sciences develops molecular profiling and AI-driven technologies to support precision medicine in oncology. The company offers a comprehensive tumor profiling service known as Caris Molecular Intelligence, which analyzes DNA, RNA, and proteins to help oncologists identify potential treatment options. Caris also operates a platform calledCaris CODEai that integrates molecular data with clinical outcomes to support research and drug development. Its services cater to biopharma partners, healthcare providers, and academic institutions aiming to improve cancer diagnostics and therapy selection. The company incorporates machine learning models to discover new biomarkers and therapeutic targets based on large-scale multi-omic data. | $168M / Private Equity / Apr 07, 2025 | |
| See all 36 investments → | |||
Co-Investors
Deep Track Capital
11 deals together
RA Capital Management
9 deals together
Venrock Healthcare Capital Partners
9 deals together
Fairmount Funds Management
8 deals together
Perceptive Advisors
8 deals together
OrbiMed
7 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
Health Care Investors in United States
21,541 investors
FAQ
What does Braidwell invest in?
Braidwell invests primarily in Biotechnology, Health Care and Biopharma startups, most often at Post-IPO Equity and Series A stage. Most of the 36 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Braidwell?
Public channels for Braidwell include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Braidwell?
The team at Braidwell includes Narendra Nayak (Partner) and Ilan Sender (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
